OGN
Organon & Co
NYSE: OGN · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
$13.33
-0.30% today
Updated 2026-06-05
Market cap
$3.53B
P/E ratio
14.45
P/S ratio
0.57x
EPS (TTM)
$0.93
Dividend yield
0.59%
52W range
$6 – $13
Volume
9.7M
WallStSmart proprietary scores
58
out of 100
Grade: C+
Hold
Investment rating
5.3
Growth
C+4.0
Quality
C7.0
Profitability
B+7.7
Valuation
B+3/9
Piotroski F-Score
Weak
1.1
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →199 stocks currently score above 75
Price targets
Analyst target
$11.25
-15.60%
12-Month target
$4.88
-63.39%
Intrinsic (DCF)
$12.46
Margin of safety
+38.28%
0 Strong Buy0 Buy4 Hold0 Sell1 Strong Sell
Price chart
Stock snapshot
Strengths
+ ROE 34.10% — strong efficiency
+ Free cash flow $188.00M — positive
+ 38.28% below intrinsic value
Risks
- Piotroski 3/9 — weak financial health
- Altman Z 1.06 — distress zone
- Thin margins at 3.99%
- Revenue declining -3.50% QoQ
- Debt/equity 9.49x — high leverage
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $6.17B | $6.26B | $6.40B | $6.22B | $6.16B |
| Net income | $917.00M | $1.02B | $864.00M | $187.00M | $146.00M |
| EPS | — | — | — | — | $0.93 |
| Free cash flow | $431.00M | $538.00M | $588.00M | $538.00M | $188.00M |
| Profit margin | 14.85% | 16.33% | 13.49% | 3.01% | 3.99% |
Peer comparison
Smart narrative
Organon & Co trades at $13.33. representing a P/E of 14.45x trailing earnings. Our Smart Value Score of 58/100 indicates the stock is fair. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 1.06, it sits in the distress. TTM revenue stands at $6.16B. with profit margins at 3.99%. Our DCF model estimates intrinsic value at $12.46.
Frequently asked questions
What is Organon & Co's stock price?
Organon & Co (OGN) trades at $13.33, on a P/E of 14.5x and a P/S of 0.6x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Organon & Co overvalued?
Organon & Co carries a Smart Value Score of 58/100 (Grade C+), which we rate Hold. That score blends growth, quality, and valuation into one read. Our DCF puts intrinsic value at $12.46 versus the $13.33 price, a 38.3% margin of safety on a cash flow basis.
What is the price target of Organon & Co (OGN)?
The 12-month analyst consensus target is $11.25, about 15.6% below the current $13.33. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the intrinsic value of Organon & Co (OGN)?
Our DCF model estimates intrinsic value at $12.46, a +38.3% margin of safety versus today's $13.33. Intrinsic value is what the projected cash flows are worth today. A positive reading means the price sits below that estimate, leaving a cushion if growth holds.
What is Organon & Co's revenue?
Organon & Co's trailing twelve-month revenue is $6.16B. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Organon & Co's Altman Z-Score is 1.06, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - GENERAL
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio0.57x
ROE34.10%
Beta1.54
50D MA$11.74
200D MA$9.01
Shares out0.26B
Float0.26B
Short ratio—
Avg volume9.7M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—